Human Digital Twins (HDTs) are transforming drug discovery, clinical trials, and personalised medicine.

• Are they the key to faster, safer drug development? What’s the realistic timeline for widespread adoption, and who will lead the way? 
• Can HDTs accurately predict drug efficacy and patient responses better than traditional trials? 

• What are the regulatory and ethical hurdles in using digital twins for clinical trials? 

• How do we bridge the gap between AI-driven predictions and real-world biological variability?